Bisphosphonates fail to prevent breast cancer in postmenopausal women

  • Rouach V & al.
  • J Bone Oncol
  • 1 Jun 2019

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A large Israeli observational study of osteoporotic or osteopenic postmenopausal women fails to show that exposure to bisphosphonates protects against breast cancer onset.

Why this matters

  • This observational study using 5 levels of exposure does not support 2 prior observational studies, but does support the negative results of prior randomized controlled trials.
  • The evidence suggests that positive studies might reflect low estrogen rather than an antitumor effect of bisphosphonates.

Study design

  • Historical prospective study (n=11,717) using databases of the Israeli Maccabi Healthcare Services (MHS).
  • Exposure to bisphosphonates (alendronate or risedronate) among postmenopausal women with osteoporosis of osteopenia was stratified into quintiles of proportion of days covered (PDC) with bisphosphonates during the follow-up, which was a minimum of 5 years.
  • Breast cancer incidence was obtained from the Israel National Tumor Registry.
  • Funding: None.

Key results

  • 173 incident breast cancers were seen over a total of 130,252 person-years of follow-up.
  • Compared with PDC of 20% or lower (the lowest quintile of exposure), the adjusted HRs for breast cancer at higher quintiles were:
    • PDC 21%-40%: HR, 0.816; P=.455.
    • PDC 41%-60%: HR, 0.818; P=.420.
    • PDC 61%-80%: HR, 0.727; P=.179.
    • PDC 81%-100%: HR, 1.146; P=.504.

Limitation

  • Multiple comparisons.